Related references
Note: Only part of the references are listed.Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial
Jack Cuzick et al.
LANCET (2014)
Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline
Kala Visvanathan et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial
Pascal Pujol et al.
FAMILIAL CANCER (2012)
Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older
Andrew N. Freedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Exemestane for Breast-Cancer Prevention in Postmenopausal Women
Paul E. Goss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer
Victor G. Vogel et al.
CANCER PREVENTION RESEARCH (2010)
Reduction in proliferation with six months of letrozole in women on hormone replacement therapy
Carol J. Fabian et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
A breast cancer prediction model incorporating familial and personal risk factors
J Tyrer et al.
STATISTICS IN MEDICINE (2004)